Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own1.80% Shs Outstand46.11M Perf Week3.69%
Market Cap1.17B Forward P/E15.37 EPS next Y1.65 Insider Trans-24.44% Shs Float45.30M Perf Month20.48%
Income-34.60M PEG- EPS next Q0.09 Inst Own- Short Float9.98% Perf Quarter19.06%
Sales519.60M P/S2.25 EPS this Y-401.70% Inst Trans-1.44% Short Ratio6.14 Perf Half Y1.81%
Book/sh14.60 P/B1.73 EPS next Y59.19% ROA-2.70% Target Price33.10 Perf Year-27.38%
Cash/sh- P/C- EPS next 5Y29.00% ROE-5.20% 52W Range16.40 - 37.36 Perf YTD34.57%
Dividend- P/FCF- EPS past 5Y-24.60% ROI-2.90% 52W High-32.28% Beta1.63
Dividend %- Quick Ratio0.50 Sales past 5Y12.20% Gross Margin79.20% 52W Low54.27% ATR1.21
Employees535 Current Ratio0.50 Sales Q/Q7.40% Oper. Margin-6.90% RSI (14)68.88 Volatility5.12% 5.21%
OptionableYes Debt/Eq0.50 EPS Q/Q-132.60% Profit Margin-6.70% Rel Volume0.89 Prev Close25.30
ShortableYes LT Debt/Eq0.04 EarningsFeb 14 BMO Payout- Avg Volume736.44K Price25.30
Recom2.50 SMA2013.76% SMA5020.59% SMA2009.50% Volume656,327 Change0.00%
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Apr-22-15Resumed Piper Jaffray Neutral
Feb-12-15Initiated MLV & Co Buy $58
Oct-30-14Reiterated MKM Partners Neutral $31.50 → $33
Aug-19-14Resumed Stifel Buy $47
May-07-14Reiterated MKM Partners Neutral $33 → $31.50
Apr-17-14Initiated Canaccord Genuity Hold $37
Apr-14-14Upgrade FBR Capital Mkt Perform → Outperform $30 → $47
Nov-01-13Upgrade MKM Partners Sell → Neutral
Nov-01-13Reiterated FBR Capital Outperform $35 → $30
Oct-30-13Initiated FBR Capital Mkt Perform $35
Oct-01-13Reiterated Aegis Capital Buy $43 → $50
Aug-01-13Reiterated Feltl & Co. Buy $40 → $43
May-02-13Downgrade MKM Partners Neutral → Sell
Apr-16-13Reiterated MKM Partners Neutral $31 → $33
Feb-21-17 07:00AM  Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors Business Wire
Feb-16-17 01:20PM  Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR) at Insider Monkey
12:52PM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
Feb-15-17 04:45PM  Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC +6.50%
03:23PM  [2/15] Today's Top 10 Long/Short Estimize Signal Scores
10:55AM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
09:42AM  Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
09:27AM  Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
06:35AM  Acorda Therapeutics upgraded by Goldman
Feb-14-17 12:38PM  Edited Transcript of ACOR earnings conference call or presentation 14-Feb-17 1:30pm GMT
09:30AM  The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
08:30AM  Acorda Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Acorda Therapeutics Inc Earnings Release - Before Market Open
06:27AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:19AM  Acorda reports 4Q loss
06:00AM  Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 Business Wire
Feb-10-17 10:19AM  A Loud Coaching Session on the Desk
08:15AM  Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
08:15AM  Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial Accesswire
07:07AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events
Feb-09-17 05:00PM  Acorda Pops To 19-Week High On Strong Parkinson's Drug Trial +20.83%
02:03PM  Acorda Parkinsons drug results shot its stock up 13%. Why Wall Street is still cautious at MarketWatch
11:07AM  Why Acorda Therapeutics Stock Is Jumping Today at Motley Fool
11:00AM  Acorda Therapeutics Stock Surges on Clinical Trial Results at TheStreet
10:38AM  Acorda Parkinsons Drug Succeeds In Phase 3 Study at Investopedia
10:25AM  Is This The Big Turnaround Acorda Needs?
09:37AM  Acorda stock surges 9% after positive late-stage clinical trial results for Parkinson's drug at MarketWatch
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
07:49AM  Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study
06:38AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 Business Wire
Feb-07-17 10:35AM  [2/7] Today's Top 10 Long/Short Estimize Signal Scores
10:00AM  Biotechnology Executives Oppose Trump Immigration Policy at Forbes
Feb-03-17 07:00AM  Acorda Therapeutics to Present at Two Investor Conferences in February Business Wire
Feb-02-17 08:42AM  Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
06:46AM  Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
06:42AM  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Jan-31-17 07:00AM  Acorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14, 2017 Business Wire
Jan-30-17 08:31AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : January 30, 2017
Jan-25-17 09:30AM  The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Jan-24-17 12:30PM  Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market? at Insider Monkey
08:14AM  Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
Jan-23-17 05:03PM  Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
Jan-18-17 08:28AM  Kura Oncology Starts Dosing Patients in Phase II CMML Study
Jan-17-17 08:05AM  What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Jan-09-17 06:25AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:00AM  Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference Business Wire
Jan-05-17 08:15AM  Post Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing Accesswire
08:12AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : January 5, 2017
Jan-03-17 02:42PM  New year, new drug prices
Dec-30-16 03:36PM  January Will Feature Some Of The Market's Most Influential Events
Dec-28-16 07:00AM  Acorda Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-21-16 09:28AM  Acorda Therapeutics, Inc. Value Analysis (NASDAQ:ACOR) : December 21, 2016
Dec-20-16 07:37AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : December 20, 2016
Dec-14-16 11:29PM  Is Genomic Health, Inc. (GHDX) A Good Stock To Buy? at Insider Monkey
Dec-09-16 12:23PM  These small-cap stocks are expected to rise at least 31% in 2017 at MarketWatch
Dec-02-16 12:59PM  Is Kearny Financial (KRNY) A Good Stock To Buy? at Insider Monkey
Nov-28-16 10:21AM  Acorda Therapeutics Inc (ACOR) Continues To Fall From Favor With Top Investors at Insider Monkey
Nov-23-16 06:31AM  Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola
Nov-22-16 04:38PM  Biotech Movers And Shakers: Mast Therapeutics, Inc. (MSTX) And Acorda Therapeutics Inc (ACOR) at Insider Monkey
08:53AM  Acorda Stops Post-Stroke Development Program on Ampyra
08:00AM  What Trump isn't saying about drugmakers matters to investors at CNBC
07:00AM  Acorda Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-21-16 06:34PM  In Case You Missed It Monday: Markets Punch Through Record Highs
04:43PM  Dow, S&P, Nasdaq Close At Record Highs; Oil Surges 4% at Barrons.com
04:19PM  Acorda Scrapping Stroke Drug Just 'Small Disappointment': RBC
11:39AM  Why Acorda Therapeutics Stock Is Slumping Today at Motley Fool
11:36AM  Acorda Therapeutics: Punished By A "Small Disappointment" at Barrons.com
10:04AM  Acorda Slides on Clinical Study Update
09:25AM  Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug development at MarketWatch
09:17AM  Stocks to Watch: LifeLock, Tyson Foods, Headwaters at The Wall Street Journal
09:08AM  Acorda Stroke Study Fails, Dampening Revenue Growth Plans
08:58AM  Acorda Therapeutics sinks 13% on discontinuation of drug for post-stroke walking at MarketWatch
06:50AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties Business Wire
Nov-20-16 01:25PM  5 Trade Ideas for Monday: Acorda Therapeutics, Aflac, BlackRock, Cirrus Logic and Foot Locker
Nov-17-16 01:04PM  ACORDA THERAPEUTICS INC Financials
Nov-16-16 11:32AM  ETFs with exposure to Acorda Therapeutics, Inc. : November 16, 2016
Nov-15-16 07:35AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : November 15, 2016
Nov-09-16 07:00AM  Acorda Therapeutics to Present at the Stifel 2016 Healthcare Conference Business Wire +10.83%
Nov-07-16 05:37PM  ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report +5.33%
03:30PM  Gurus' 6 Worst-Performing Stocks
Nov-06-16 11:52PM  3 Best Biotech Stocks of the 21st Century (So Far) at Motley Fool
Oct-28-16 08:25AM  Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y
Oct-27-16 02:36PM  Edited Transcript of ACOR earnings conference call or presentation 27-Oct-16 12:30pm GMT -7.59%
01:16PM  ETFs with exposure to Acorda Therapeutics, Inc. : October 27, 2016
08:30AM  Acorda Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q3 2016 Acorda Therapeutics Inc Earnings Release - Before Market Open
06:44AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:32AM  Acorda reports 3Q loss
06:00AM  Acorda Provides Financial and Pipeline Update for Third Quarter 2016 Business Wire
Oct-17-16 07:00AM  Acorda to Host Conference Call to Discuss Third Quarter 2016 on October 27, 2016 Business Wire
Oct-13-16 07:31AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.16%
07:00AM  Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinsons Disease Published in Science Translational Medicine Business Wire
Oct-12-16 07:00AM  Acorda Named One of the Best Workplaces by Fortune Magazine and Great Place to Work Business Wire
Oct-05-16 07:01AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
Oct-04-16 06:00AM  Acorda Announces Departure of Michael Rogers Business Wire
Sep-30-16 07:16AM  ACORDA GAINS TITLE TO BIOTIE SHARES AND THE SHARES WILL DELIST GlobeNewswire
Sep-27-16 08:32AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : September 27, 2016
Sep-26-16 04:04PM  Deutsche Bank, Kroger Slip into Mondays 52-Week Low Club at 24/7 Wall St. -15.73%
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that is in the Phase IIb clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; and Ampyra/Dalfampridine that is in the Phase I pharmacokinetic studies for the treatment of chronic post-stroke deficits. Further, it develops Plumiaz, a proprietary nasal spray formulation of diazepam to treat people with epilepsy; Cimaglermin alfa/Neuregulins that has completed a Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blight AndrewChief Scientific OfficerFeb 09Option Exercise22.1367,5861,495,678144,144Feb 13 04:13 PM
Greene Barry EDirectorFeb 09Option Exercise22.1372316,000723Feb 13 04:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Option Exercise22.1363,1831,398,24067,719Feb 13 04:15 PM
Wasman JanePresident, Intl and GCFeb 09Option Exercise22.1354,5361,206,882156,210Feb 13 04:16 PM
Wasman JanePresident, Intl and GCFeb 09Sale22.3054,5361,216,218101,674Feb 13 04:16 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Sale22.3263,1831,410,5424,536Feb 13 04:15 PM
Greene Barry EDirectorFeb 09Sale22.6572316,3760Feb 13 04:14 PM
Blight AndrewChief Scientific OfficerFeb 09Sale22.4167,5861,514,37976,558Feb 13 04:13 PM
Greene Barry EDirectorJan 03Option Exercise15.913,01748,0003,017Jan 05 04:12 PM
Greene Barry EDirectorJan 03Sale19.263,01758,1130Jan 05 04:12 PM
COHEN RONPresident and CEODec 14Option Exercise15.4940,172622,264519,860Dec 16 08:08 AM
COHEN RONPresident and CEODec 14Sale20.7540,172833,655479,688Dec 16 08:08 AM
Blight AndrewChief Scientific OfficerDec 01Sale20.764,855100,77476,558Dec 05 05:03 PM
Wasman JanePresident, Intl and GCDec 01Sale20.743,34769,400101,674Dec 05 05:15 PM
Sabella Lauren MChief Commercial OfficerDec 01Sale20.742,42950,38111,949Dec 05 05:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 01Sale20.744,41691,5944,536Dec 05 05:11 PM
Hindman Andrew A.Chief Business Dev. OfficerDec 01Sale20.724439,18049,227Dec 05 05:09 PM
COHEN RONPresident and CEODec 01Sale20.747,160148,482479,688Dec 05 05:08 PM
BLANK BURKHARDChief Medical OfficerDec 01Sale20.7410,000207,44240,000Dec 05 05:06 PM
Batycky Richard P.Chief Tech. Off. & Site HeadOct 21Sale20.302,06341,87745,916Oct 25 07:06 AM
LAWRENCE DAVIDChief, Bus. Ops & PAOOct 07Sale20.822505,2058,952Oct 11 07:31 AM
Wasman JanePresident, Intl and GCOct 03Sale20.783,75077,927105,021Oct 05 04:18 PM
Wasman JanePresident, Intl and GCSep 23Option Exercise8.505004,250109,271Sep 27 08:01 AM
Wasman JanePresident, Intl and GCSep 23Sale27.3250013,660108,771Sep 27 08:01 AM
Blight AndrewChief Scientific OfficerAug 09Option Exercise22.139,754215,85681,413Aug 11 03:54 PM
LAWRENCE DAVIDChief of Business OperationsJun 22Option Exercise8.505004,2509,702Jun 24 07:34 AM
LAWRENCE DAVIDChief of Business OperationsJun 22Sale25.0950012,5459,202Jun 24 07:34 AM
Wasman JanePresident, Intl and GCJun 10Option Exercise22.138,647191,358108,771Jun 14 08:42 AM
RAUSCHER STEVEN MDirectorJun 08Option Exercise18.651,08620,2541,086Jun 10 07:25 AM
RAUSCHER STEVEN MDirectorJun 08Sale27.831,08630,2240Jun 10 07:25 AM
Hindman Andrew A.Chief Business Dev. OfficerMay 13Sale26.114,860126,88549,670May 16 03:12 PM
Randall LorinDirectorApr 19Option Exercise18.651,48827,7511,488Apr 21 07:57 AM
Randall LorinDirectorApr 19Sale28.681,48842,6760Apr 21 07:57 AM